Warning letter
Bristol-Myers Squibb Manufacturing Company: warning letter of Oct 23, 2002
FDA warning letter UCM145263 · San Juan District Office
Key facts
| Reference number | UCM145263 |
|---|---|
| Company | Bristol-Myers Squibb Manufacturing Company |
| Subject | CGMP for Finished Pharmaceuticals/CGMP in Manufacturing, Processing, Packing, or Holding/Adulterated |
| Issue date | Oct 23, 2002 |
| Posted date | Oct 23, 2002 |
| Issuing office | San Juan District Office |
| Product type | Drugs |
| CFR sections cited | 211.111, 211.166, 211.110(a) |
| Country | 3 |
| Inspection city | Mayaguez |
| Inspection ZIP | 00680 |
| Inspection start date | Jul 3, 2002 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: